Brief: Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement
25/09/2026 12:02
BRIEF-Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement Sept 25 (Reuters) - Eli Lilly and Company LLY.N:
NEKTAR THERAPEUTICS - JURY FINDS LILLY BREACHED IMPLIED COVENANT OF GOOD FAITH IN LICENSE AGREEMENT - SEC FILING
NEKTAR THERAPEUTICS - JURY AWARDS NEKTAR THERAPEUTICS $90 MILLION IN DAMAGES PLUS INTEREST - SEC FILING
NEKTAR THERAPEUTICS - JURY VERDICT SUBJECT TO POST-TRIAL PROCEEDINGS AND POSSIBLE APPEAL - SEC FILING
Source text: [ID:n0001213900-26-103215]
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says